Pazopanib patent expiry date?

Pazopanib Patent Expiry Date: What You Need to Know

Pazopanib is a medication used to treat certain types of cancer, including renal cell carcinoma (RCC) and soft-tissue sarcoma. It is marketed under the brand name Votrient and is widely used in clinical practice.

Current Patent Status

According to the database DrugPatentWatch.com [1], the patent for pazopanib is owned by GlaxoSmithKline and has been the subject of various patent disputes. The key patents for pazopanib are expected to expire in 2026, although specific dates may vary depending on the jurisdiction.

Exclusivity Expiration Timeline

Pazopanib patents are set to expire in different countries at various times. The key patents have been scheduled for expiration:

- US: 2026 ( Patent No. 7,943,788)
- EU: 2027 ( EP 1 864 142 B1 patent)

Generic Entry Timeline

Generic manufacturers will likely be able to enter the market once the patents expire, and biosimilars are expected to be approved. The entry of generics will depend on various factors, including the patent expiry dates and regulatory approvals.

Impact on Patients

The expiry of pazopanib patents may lead to increased competition, potentially resulting in lower prices and wider availability of the medication.

Competitors

Several generic and biosimilar versions of pazopanib are already in development, with some nearing regulatory approval. These alternatives will likely offer significant cost savings without compromising efficacy and safety profiles [2].

Regulatory Landscape

Regulatory agencies around the world, such as the FDA and EMA, will play a crucial role in overseeing the development and approval of generic and biosimilar versions of pazopanib.

Sources:

[1] DrugPatentWatch.com - Pazopanib patents.

[2] Clinical trials data on generic and biosimilar versions of pazopanib.